tecovirimat siga
siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirales para uso sistémico - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 y 5. tecovirimat siga should be used in accordance with official recommendations.
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - inmunosupresores - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - inmunosupresores - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
amvuttra
alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - otras drogas del sistema nervioso - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
pombiliti
amicus therapeutics europe limited - cipaglucosidase alfa - enfermedad de almacenamiento de glucógeno tipo ii - otros tracto alimentario y metabolismo de los productos, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - los agentes antineoplásicos - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leucemia, mieloide - agentes antineoplásicos - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.
orserdu
stemline therapeutics b.v. - elacestrant - neoplasias de la mama - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
liverplex-b solución inyectable
krona internacional - solución inyectable
liverfast 5mg tableta recubierta
drogueria tobal s.a.c. - droguerÍa - tableta recubierta - por tableta - - desloratadina